The Conservative Party Prime Ministerial candidate Rishi Sunak visited Bassett Pharmacy in Southampton on Wednesday (Aug 24) - the pharmacy that used to be
run by his family.
During the visit, Sunak is reported to have said that he intends to reform the NHS and achieve value for money from health spending, should he become prime minister.
Giving his reaction to the visit, National Pharmacy Association (NPA) chief executive Mark Lyonette said: "If Rishi Sunak is serious about NHS reform, he would do
well to start with a 'pharmacy first' approach to prevention and treatment which has the potential to transform the way people access NHS care.
"That can only happen with a sustained increase in funding for our sector, which is facing much harder times now than it ever did when Mr Sunak's parents owned a
pharmacy years ago."
Earlier in the week, NPA board member Hiten Patel met the former chancellor when he visited West Harrow for a campaign event on August 23. Patel took the opportunity
to explain that pharmacies in England are not being properly supported to fulfil their potential within the NHS.
The British Generic Manufacturers Association (BGMA) has published a positioning paper which sets out the objectives that need to be delivered through the
next Voluntary Pricing and Access Scheme (VPAS) on Thursday (15 June).
The paper details how a financially sustainable VPAS can support widened medicines access to patients.
VPAS is an agreement between the Department of Health and Social Care (DHSC), NHS England and The Association of the British Pharmaceutical Industry (ABPI).
The scheme aims to limit increases in spending on branded medicines to no more than 2% per year via a rebate system which is charged on companies' sales revenues.
Two years ago, the rate was 5.1% but for 2023 it has soared to 26.5%. Last year, the association had raised concerns over the rise in the VPAS rate for 2023 to
26.5 per cent.
"The rocketing rate is in large part due to the growth in spend in on-patent medicines since 2019. Looking at the four completed years of the current VPAS scheme,
data shows that the average annual growth rate for on-patent medicine sales value from 2019-22 was 18% compared to just 2% for off-patent products," said the
association.
The British Generic Manufacturers Association (BGMA) has elected Diane DiGangi Trench to be its new vice-chair.
DiGangi Trench takes up the position replacing Xiromed's Peter Ballard and in 12-months' time will assume the association's chair role from Accord's Peter Kelly.
With over 25 years of pharmaceutical industry experience, DiGangi Trench has held a number of senior commercial roles including stints with Takeda and Astra Zeneca.
She joined Sandoz in 2018 in the US, where she served as Vice-President, Market Access and Patient Services.
In 2021, she became the head of Sandoz' UK business and in her two years in role, she has led the organisation through a post-COVID recovery and growth phase to
prepare for the proposed spin out of the company from its parent, Novartis, expected later this year.
She said: "It's a great honor to take on the role of Vice Chair of the BGMA. The success of the generics and biosimilar industry is essential to the functioning of
the NHS. Generic medicines fill four out of five UK prescriptions and biosimilars enable the NHS to expand access to more patients. I am passionate about increasing
the sustainability of our industry so we can continue to play our vital part in the health of the nation."
Mark Samuels, BGMA chief executive, said: "We are extremely fortunate to be able to call upon the expertise of Diane who has already added significant value through
her role on the BGMA board and leadership of a key strategic committee.
The government, NHS England and the Association of the British Pharmaceutical Industry (ABPI) has begun the negotiations for a new voluntary scheme for
branded medicines pricing on Thursday (4 May).
A new voluntary scheme is expected to take effect from 1 January 2024, replacing the current scheme which came into force in 2019 and ends on 31 December 2023
In their first meeting, the government, NHS England and industry - represented by the ABPI -expected to agree to a shared negotiation aim of working toward a
mutually beneficial agreement that supports better patient outcomes and a healthier population, a financially sustainable NHS, and UK economic growth.
Health Minister, Will Quince, said: "These negotiations will ensure a new scheme continues to deliver value for money by providing significant savings for our
health services, securing access to innovative lifesaving drugs for NHS patients, and helping to reduce waiting times - one of the Prime Minister's 5 priorities.
The current voluntary scheme supports investment in NHS services and saves billions of pounds for the NHS, while also promoting innovations and a successful life
sciences sector.
The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price.
The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel
disease and psoriasis, has accounted for about one third of the savings.
After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions,
which have the same quality, safety and efficacy of a branded one.
Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to
aggressive blood cancers.
Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality
patient care.
NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.
Walgreens Boots Alliance on Tuesday (June 28) scrapped the plan to sell its UK high street pharmacy chain saying no third party was able to make an adequate
offer due to the turmoil in global financial markets.
Walgreens' move to call off the sale comes as private equity bidders Apollo Global and TDR faced headwinds in raising financing for the deal, as banks were wary
of underwriting large chunks of the financing due to tough market conditions.
Boots was initially valued at as much as £8bn with the auction process being led by Goldman Sachs.
Global economic uncertainty and rising inflation have triggered a spike in interest rates as central banks have rushed to take action in the most widespread
tightening of monetary policy for more than two decades, making deal financing costlier and harder to access.
Walgreens had put its Boots UK business up for sale after announcing a strategic review in January as the second-largest US pharmacy chain renewed its focus on
domestic healthcare.
The company said the decision to retain Boots and No7 Beauty Company was also underpinned by their ongoing strong performance.
Boots has become the first community pharmacy in the UK to transport prescription medicines by a drone.
The pharmacy multiple completed a test flight transporting prescription-only medicines by drone from Portsmouth to the Isle of Wight earlier this month.
The flight departed from the British Army's Baker Barracks on Thorney Island near Portsmouth and arrived at St. Mary's Hospital on the Isle of Wight. The medicines
were collected by Boots personnel and transported to the multiple's pharmacies across the island, where they will be dispensed to patients with prescriptions for them.
Boots worked with medical drone start-up Apian to facilitate the test flight and is now assessing the future potential for drones in medicines delivery.
Rich Corbridge, chief information officer at Boots, said: "Drones have a huge potential in the delivery of medicines and it is incredibly exciting to be the first
community pharmacy in the UK to transport them in this way. An island location like the Isle of Wight seemed like a sensible place to start a trial of drones and
their value to the delivery of medicines to more remote locations is very clear.
Boots is planning to invest more than £3.5 million to accelerate its capacity to offer prescribing services in its stores across England.
The company is inviting 500 of its pharmacists to apply for a bursary which will cover the cost of pharmacist independent prescriber (PIP) courses starting this
September.
The value of the bursary is up to £7,000 per pharmacist, and it will enable time off work for those who need it to complete the training.
The move by Boots will support its current pharmacists to gain this qualification via courses accredited by the General Pharmaceutical Council (GPhC). From 2026,
all qualified pharmacists will be able to prescribe as part of new curricula for pharmacy degrees.
Under current GPhC guidelines and with an independent prescribing qualification, pharmacists can prescribe autonomously for any condition within their clinical
competence.
Marc Donovan, the chief pharmacist at Boots, said the ambition of the company was "to have a pharmacist prescriber available at every store".
Dental procedures are a necessary evil for most people. We all know that we need to go in for a cleaning and check-up at least once a year, but sometimes
the cost of these procedures can be prohibitive. It's hard to know which procedures are worth the money and which ones aren't. Here is an essential list of dental
procedures that are worth the money.
CAVITY FILLINGS
Cavities are caused by tooth decay. If left untreated, cavities can cause severe damage to your teeth. They can also lead to pain and infection. The best way to
treat a cavity is to have it filled by a dentist.
During the procedure, your dentist will remove the decay from your tooth and then fill the cavity with a composite material. This material is solid and durable and
can help restore your tooth to its original shape and function. Modern materials and techniques have made cavity fillings much more effective than they used to be.
Most fillings last for many years with proper care.
ROOT CANALS
It's a dental procedure that is used to treat an infected tooth. During the procedure, the dentist will remove the infected tissue from the tooth and then fill the
space with a particular material.
The procedures are very effective in treating infected teeth. They can also help to prevent the spread of infection to other teeth.
Root canals are usually very successful, and most teeth with a root canal can last for many years. Generally, the cost of the procedure will depend on the severity
of the infection and the number of teeth that need to be treated. If you are considering treatment for a root canal, it is crucial to find a qualified and
experienced dentist who has experience. You want a team that assures you of world-class standards in all their procedures. This is what brings you value for your
money.
Authorities in Northern Ireland have seized more than 242,000 unlicensed prescription tablets purchased online and destined for addresses throughout NI.
The medicines seized include Diazepam, used for anti-anxiety treatment, Pregabalin, used for epilepsy and anxiety, steroids and Zopiclone.
Other prescription medicines recovered included Tamoxifen, often used in the treatment of breast cancer and Salbutamol inhalers, frequently used in the treatment
of asthma.
"Co-operation between law enforcement agencies and government departments has led to the seizure of over 242,000 illegal and unlicensed tablets purchased online
and destined for addresses throughout Northern Ireland," justice minister Naomi Long was reported as saying.
The minister, together with health minister Robin Swann and assistant chief constable Mark McEwan PSNI were highlighting Northern Ireland's input to the global,
Interpol co-ordinated Operation Pangea XV, which saw multiple packages of tablets intercepted and seized, with a street value of almost £250,000.
She praised the concerted efforts made by PSNI, Border Force and officials from the Department of Health Medicines Regulatory Group during a specific week of action
in June.
Living with diabetes can be managed by proper medication. However, you may have questions regarding the medications available to you. Here, we will take a
closer look at two medications, Ozempic and Saxenda, so that you can see how these medications can impact your health.
A CLOSER LOOK AT DIABETES
Diabetes can be divided into two categories, type 1 diabetes (T1D) and type 2 diabetes (T2D).
Type 1 diabetes is an autoimmune disorder and is commonly diagnosed in children. Individuals with T1D require lifelong insulin treatment to manage their diabetes.
Type 2 diabetes is diagnosed later in life due to genetics, lifestyle, and other risk factors. Unlike T1D, there are numerous treatment options other than insulin
therapy to manage type 2 diabetes.
GLP-1 RECEPTOR AGONISTS
A common drug class used to treat type 2 diabetes is glucagon-like peptide 1 (GLP-1) receptor agonists. GLP-1 receptor agonists work by lowering blood glucose and
slowing gastric emptying. Benefits of using a GLP-1 receptor agonist include: weight loss, atherosclerotic cardiovascular disease (ASCVD) benefits, lowering A1C
values, and chronic kidney disease (CKD) benefits with little risk of hypoglycemia. Common GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea,
weight loss, and injection site reactions. GLP-1 receptor agonists should not be used in patients with a personal or a family history of medullary thyroid cancer.
The Department of Health and Social Care (DHSC) has introduced new arrangements for the application of discount deduction to community pharmacy payments which
will be implemented in six financial quarters beginning in October 2022 and concluding in January 2024.
Under the new discount deduction system, the current single scale will be split into three groups: one each for generic medicines, branded medicines, and appliances.
Separate fixed deduction rates have been determined for each group.
This will provide all pharmacies the same rates of deduction applied to their reimbursement for the three different groups, regardless of the total value of that
reimbursement.
Fin McCaul, PSNC member and independent community pharmacy contractor, said: "The discount deduction scale has been a point of contention for contractors for many
years, and PSNC has long been pushing to remedy this.
"The incoming changes are designed to both improve equity of access to margin and manage the distortions presented by branded medicines, which just don't have the
same level of discount available as generics.
Walgreens Boots Alliance, Boots UK's parent company, has appointed Tim Wentforth as its new CEO, effective on 23 October.
He joined WBA at a pivotal time when the company plans to downsize the business while driving execution and creating greater value for employees, patients,
customers and shareholders.
Wentforth replaced Rosalind Brewer, who stepped down on 1 September, after two years at the helm.
He joined from Evernorth, Cigna's health services organisation based in Connecticut, where he served as its founding CEO.
Prior to Cigna, he also held top roles in companies including specialty pharmacy company Accredo and pharmacy benefit manager Express Scripts.
Following the UK government's new pay offer to NHS consultants, the Royal College of Nursing (RCN) wrote to the Health Secretary Victoria Atkins calling for
fresh negotiations about nursing pay in England last week.
However, the Department of Health and Social Care (DHSC) has rejected their demand, stating that there is no basis to reopen talks as the pay deal was accepted by
the NHS Staff Council.
In the previous pay deal, nurses were given a one-off payment between £1,655 and £3,789 for 2022/23, and a 5 per cent consolidated pay increase for the 2023/24
financial year.
Nursingnotes quoted a DHSC spokesperson as saying: "We hugely value the hard work of NHS nurses and that is why we provided a 5 per cent pay rise.
"We also provided two significant non-consolidated awards, which for nurses at the top of Band 5 was over £2,000, equivalent to an extra 6.1 per cent of their
basic pay.
Diabetes affects over 537 million people worldwide; by 2045, this is estimated to increase to 783 million. [1] With the growing prevalence of diabetes,
it's even more important to utilise all options to support people with diabetes (PwDs) in managing their daily life with diabetes.
Where do PwDs most often access healthcare support? On average, PwDs visit the pharmacy three-to-eight times more than the general population to obtain medicines
and testing supplies.[2] It is clear that pharmacists play an integral role in empowering the self-management needs of PwDs beyond the traditional role of
supplying medicines. This relationship, however, may be underutilised.
Research suggests there is a lack of broad recognition of pharmacists as a key source of diabetes care, and that resource constraints - particularly following
the COVID-19 pandemic - can interfere with patient education provision and training.[3,4] Furthermore, the circumstances and role of the pharmacy vary, nationally
and internationally. At Roche Diabetes Care we would like to shine a light on the increasing value of community pharmacists as important figures in the well-being
of PwDs.
The MHRA's Criminal Enforcement Unit (CEU), working with other law enforcement partners, has seized more than two million "illegally traded medicines" this
year, with a total value of £5 million.
The products confiscated in the UK were prescription-only medicines including anti-depressants, pain medication and human growth hormones.
The MHRA launched an initiative, Operation Pangea, 15 years ago to combat "illegal internet trade in medical" products.
Andy Morling, the Deputy Director of Criminal Enforcement of MHRA, spoke about Operation Pangea's 15-year anniversary.
"Fifteen years ago, the MHRA started Operation Pangea, combining our knowledge and resources with those of international partners to disrupt and bring to justice
the criminal gangs responsible for selling medicines illegally and causing harm around the world.
The Manchester Crown Court on Friday (9 December) sentenced three men, Cleave Lewis (35) and brothers, Denis Sutherland (58) and David Sutherland (59), to a
total of three years in jail after they pleaded guilty to the illegal sale and supply online of prescription-only medicines and controlled Class B and Class C
drugs, worth more than £1.5m.
They were found in possession of nearly 1.3m tablets of prescription-only drugs, including powerful sleeping pills, painkillers and anti-anxiety meds, when officers
from the Medicines and Healthcare products Regulatory Agency (MHRA) and Greater Manchester Police searched their residential homes and business premises in October
2017.
Following investigations by the agency, they also pleaded guilty to illegally making these medicines available online on three different websites for the public to
purchase without prescriptions.
The officials also recovered controlled medicines, over half a million (525,737) erectile dysfunction, slimming and herbal tablets, with an estimated value of
approximately £500k, from them.
US drugs giant Pfizer will exit its consumer healthcare joint venture with GlaxoSmithKline after the unit is spun off next month, the British drugmaker
said Wednesday (June 1).
GSK will list the healthcare division on the London stock market on July 18 as it looks to concentrate on the pharmaceutical business, it said in a statement.
The London-listed firm currently owns a majority 68 percent of the unit, with Pfizer holding the remainder.
"Pfizer intends to exit its 32-percent ownership interest in Haleon in a disciplined manner, with the objective of maximising value for Pfizer shareholders," GSK
said.
Covid jab maker Pfizer is seeking to pursue its focus on "innovative medicines and vaccines", it noted.
The unit, which will be named Haleon after the demerger, makes products including Sensodyne toothpaste, pain relief drug Panadol and cold treatment Theraflu.
The Royal Pharmaceutical Society (RPS) has appointed Professor Parastou Donyai as chief scientist. She will take up the role in June.
Parastou is a pharmacist with a PhD in pharmacy. She also has a postgraduate diploma in Psychological Research Methods as well as a degree in Psychology.
She is currently a professor of Social & Cognitive Pharmacy at the University of Reading and her research examines the psychology of medication use, discontinuation
and decision-making processes.
Prior to this, Parastou also spent more than five years as a senior lecturer in Pharmacy Practice at Kingston University and St. George's University of London. Her
longstanding research interest includes continuing professional development in pharmacy.
Commenting on her appointment, Parastou said: "It is a real privilege for me to be the Royal Pharmaceutical Society's next chief scientist.
"As a pharmacist, scientist and academic, I look forward to working with the Royal Pharmaceutical Society's members and key stakeholders to uphold the value of
science across the breadth of our profession."
The NHS has signed the first-of-its-kind subscription deal for two antimicrobial drugs - cefiderocol and ceftazidime-avibactam, manufactured by Shionogi and Pfizer respectively - that will help around 1700 patients per year with severe bacterial infections.
Under this deal, pharmaceutical firms will receive a fixed yearly fee - capped at a level that represents value to taxpayers - in order to incentivise funding for innovation that can generate a pipeline of new antibiotics for NHS patients.
NHS said the deal will help patients with serious infections that have evolved so much that antibiotics and other current treatments are no longer effective can be
given a potentially life-saving alternative. The drugs will provide a lifeline to patients with life-threatening infections like sepsis, hospital or ventilator pneumonia and blood stream infection.
Announcing the deal at NHS ConfedExpo, NHS Chief Executive Amanda Pritchard called the revolutionary subscription deal a game-changer and the latest NHS success in using its commercial power to benefit NHS patients in line with the NHS Long Term Plan.
"Superbug-busting drugs on the NHS will save lives and strike a blow in the global battle against antimicrobial resistance," Pritchard said.